Barcelona pivots to Gabriel Jesus after Atletico blocks Alvarez move
Barcelona failed in their pursuit of Atletico Madrid's Julian Alvarez, who was their primary striker target all summer. Instead, they signed Gabriel Jesus from Arsenal on deadline day for an initial €10 million plus add-ons, with the 29-year-old taking a pay cut to join. The club also secured Rodri, who chose Barcelona over Real Madrid, while adding wingers Anthony Gordon and Karim Adeyemi earlier in the window.
Barcelona’s total outlay reached roughly €212 million across eight incoming players, including potential add-ons, while nine departures generated about €99 million, leaving a net spend near €113 million. The Alvarez pursuit collapsed due to Atletico’s firm refusal to negotiate, prompting the late pivot to Jesus, whose initial fee was a modest €10 million plus €4.5 million in bonuses. Jesus accepted a reduced salary to facilitate the move, and his pressing profile won quick approval from Hansi Flick. Elsewhere, Rodri’s decision to reject Real Madrid became a major fan talking point, while Joao Cancelo returned permanently after a loan. A proposed move for Aymeric Laporte stalled when Athletic Club signaled they would not sell despite the player’s interest. Ronald Araujo departed on loan to Liverpool, and the new-look attack has already produced 12 goals in three league matches.
This transfer window could reshape Barcelona’s competitive trajectory and fan sentiment in the near term. The failure to land Alvarez may temper expectations among supporters, though the additions of Rodri and Gabriel Jesus could restore confidence in the club’s recruitment strategy. Financially, the significant net spend signals continued ambition despite prior fiscal constraints, which may influence how fans perceive the board’s management. On the pitch, the revamped frontline could make Barcelona more unpredictable in La Liga and European competition, potentially affecting rival clubs’ planning. The outcome may also impact player morale and season-ticket enthusiasm, though long-term effects remain uncertain.